Sensus Healthcare(US:SRTS)2024-08-13 18:59Financial Performance - Revenues for the three months ended June 30, 2024, were $9.2 million, an increase of 104.4% compared to $4.5 million for the same period in 2023[79] - Gross profit for the three months ended June 30, 2024, was $5.4 million, representing a 107.7% increase from $2.6 million in the same period in 2023[81] - Net income for the three months ended June 30, 2024, was $1.6 million, compared to a net loss of $0.4 million for the same period in 2023[78] - Revenues for the six months ended June 30, 2024, were $20.0 million, an increase of 151.9% compared to $8.0 million for the same period in 2023[83] - Gross profit for the six months ended June 30, 2024, was $12.1 million, an increase of 188.1% from $4.2 million in the same period in 2023[84] Cash Flow and Receivables - Cash and cash equivalents decreased by $4.1 million from December 31, 2023, to June 30, 2024[89] - Accounts receivable increased by $7.7 million from December 31, 2023, primarily due to increased sales and extended payment terms[89] Expenses - Selling and marketing expenses decreased by 37.5% to $1.0 million for the three months ended June 30, 2024, compared to $1.6 million for the same period in 2023[82] - Research and development expenses increased by 12.5% to $0.9 million for the three months ended June 30, 2024, due to a project for a drug delivery system[83] Economic Factors - The company continues to monitor inflationary pressures and is taking actions to minimize its effects on product costs and sales[94]